First copies of Gilead coronavirus drug to start selling in Bangladesh

The Dhaka-based Beximco, which counts Norges Bank as one of its investors, will sell remdesivir for about 6,000 taka ($71) a vial to private clinics but will give it free to state-run hospitals

Topics
Coronavirus | Bangladesh | Pharma Companies

Bloomberg 

pharma
Beximco Pharmaceuticals will sell the generic version Gilead Sciences' antiviral drug.

Bangladesh’s Beximco Pharmaceuticals has become the world’s first company to start selling the generic version of Gilead Sciences’ antiviral drug on mounting urgency to treat the infection caused by the

The Dhaka-based Beximco, which counts Norges Bank as one of its investors, will sell remdesivir for about 6,000 taka ($71) a vial to private clinics but will give it free to state-run hospitals treating Covid-19 patients, Rabbur Reza, chief operating officer at the company, said in an interview.

gets order of $1 bn from US

Drug maker said on Thursday it had secured its first agreements for 400 million doses of a Covid-19 vaccine it is testing, bolstered by an investment from the US vaccine agency.

The Anglo-Swedish firm had received more than $1 billion from the US Biomedical Advanced Research and Development Authority for the development, production and delivery of the vaccine. AP/PTI

Read our full coverage on Coronavirus
First Published: Fri, May 22 2020. 02:03 IST